FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097738629> ?p ?o ?g. }

• W3097738629 endingPage "38" @default.
• W3097738629 startingPage "37" @default.
• W3097738629 abstract "Introduction: Multiple Myeloma (MM) is the second most common hematological malignancy in North America. It is characterized by invasion of the bone marrow by malignant plasma cells. This malignancy presents with a broad range of primary genomic lesions that dichotomize cases into hyperdiploidy or IgH translocated. Less recurrent secondary focal events, including indels and SNPs, are also reported, however, their clinical correlates are poorly described. In this study, we examine the exonic landscape of 26 genes reported to be mutated in &gt;1% of myeloma patients via deep sequencing using a custom panel. We assess a cohort of 76 patients banked in the QEII Myeloma Tumor Bank with detailed clinical correlates and 4 MM cell lines for their mutational profile. Methods: DNA Library preparations were performed from CD138+ cells (76 MM) and 4 MM cell lines according to Illumina TruSeq protocol and sequenced at a depth of 1000x using a custom designed mutation panel. Variants were called by six somatic variant callers and correlates with patient clinical data were assessed. Results: A total of 376 mutations were identified within 63 patients (325) and 4 cell lines (51); no mutations were identified in 13 patients. ATM was the most mutated gene and KRAS had the highest number of mutations per kilobase. Forty three patients harbored 1-4 mutations, 12 patients harbored 5-9, and 8 patients harbored ≥10 mutations. Progression-free survival (PFS) was found to be significantly reduced in patients harboring high-severity mutations (frame shift, splice site, and stop altering mutations) (n =15 HR = 2.85; 95% CI: 1.3-6.35; p = 0.01). We also assessed mutations by the pathogenicity scoring algorithms rfPred, SIFT, MutationTaster, Polyphen2, and FATHMM-FX, as well as SPLICEAI which predicts splicing impacts of mutations. FATHMM-FX was the only algorithm to identify mutations that define a group with significantly altered PFS (n = 5; HR = 6.7; 95% CI: 2.5-18; p &lt; 0.001). We then combined these indicators to define high-risk patients such that a patient is considered high risk if they harbor one or more mutations that are high-severity or predicted by FATHMM-FX to be pathogenic. Of the 376 in our cohort, 23 were high-risk markers, 19 of which were in patient samples. This classified 16 of 76 patients as high risk which had significantly reduced PFS (n = 16; HR = 3.5; 95% CI: 1.6-7.6; p = 0.002) (Fig. 1 A-B). Notably, 2 high risk mutations were found in 3 patients, one of whom had plasma cell leukemia (PCL) and the other progressed to PCL. This group had a markedly reduced PFS (n = 3; HR = 16; 95% CI: 2.9-83; p = 0.001) (Fig. 1 C-D). Additionally, focal copy-number alterations (CNVs) were probed from panel data, and patients harboring 2 or more focal CNVs had significantly reduced PFS (n = 10, HR = 3.2, 95% CI: 1-9.1, p = 0.043). Combining focal CNV and mutation risk identified 24 patients with significantly reduced PFS (HR = 4.2; 95% CI: 1.9-9.1; p &lt; 0.001) (Fig. 1 E-F). Harboring a high-risk mutation or more than one focal CNV was independent of age, ISS stage, Beta-2 microglobulin, serum albumin, LDH, and bone marrow plasma cell burden. Of 48 fluorescent in situhybridization (FISH) assessed patients, 12 had 'high risk' FISH findings, none of whom had severe mutations though 1 harbored two focal CNVs. Of the 36 patients standard-risk by FISH, 12 had high-risk mutations, and 5 had more than one panel identified focal CNV. Combined, these identified 15 high-risk patients in the FISH standard-risk group which had significantly reduced PFS (HR = 3.7; 95% CI: 1.1-12; p = 0.031) (Fig. 1 G-H). Conclusion: Our custom mutation panel demonstrates novel findings that independently redefine prognosis in multiple myeloma in our cohort of Nova Scotian patients. Figure 1 Disclosures Forward: Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Calgene: Membership on an entity's Board of Directors or advisory committees; IMV: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Astellas: Research Funding; IMV: Research Funding; Merck: Research Funding; Seattle Genetics: Research Funding. White:Karyopharm: Honoraria; Antengene: Honoraria; GSK: Honoraria; Janssen: Honoraria; Celgene: Honoraria; Takeda: Honoraria; Sanofi: Honoraria; Amgen: Honoraria." @default.
• W3097738629 created "2020-11-09" @default.
• W3097738629 creator A5002970103 @default.
• W3097738629 creator A5006781525 @default.
• W3097738629 creator A5018685925 @default.
• W3097738629 creator A5037649529 @default.
• W3097738629 creator A5047298863 @default.
• W3097738629 creator A5049410107 @default.
• W3097738629 creator A5066588179 @default.
• W3097738629 creator A5084816699 @default.
• W3097738629 creator A5091091951 @default.
• W3097738629 date "2020-11-05" @default.
• W3097738629 modified "2023-10-01" @default.
• W3097738629 title "Targeted Deep Sequencing As a Clinically Effective Approach to Profile the Mutational Landscape in Multiple Myeloma" @default.
• W3097738629 doi "https://doi.org/10.1182/blood-2020-137754" @default.
• W3097738629 hasPublicationYear "2020" @default.
• W3097738629 type Work @default.
• W3097738629 sameAs 3097738629 @default.
• W3097738629 citedByCount "0" @default.
• W3097738629 crossrefType "journal-article" @default.
• W3097738629 hasAuthorship W3097738629A5002970103 @default.
• W3097738629 hasAuthorship W3097738629A5006781525 @default.
• W3097738629 hasAuthorship W3097738629A5018685925 @default.
• W3097738629 hasAuthorship W3097738629A5037649529 @default.
• W3097738629 hasAuthorship W3097738629A5047298863 @default.
• W3097738629 hasAuthorship W3097738629A5049410107 @default.
• W3097738629 hasAuthorship W3097738629A5066588179 @default.
• W3097738629 hasAuthorship W3097738629A5084816699 @default.
• W3097738629 hasAuthorship W3097738629A5091091951 @default.
• W3097738629 hasBestOaLocation W30977386291 @default.
• W3097738629 hasConcept C104317684 @default.
• W3097738629 hasConcept C10590036 @default.
• W3097738629 hasConcept C113968399 @default.
• W3097738629 hasConcept C119054055 @default.
• W3097738629 hasConcept C121608353 @default.
• W3097738629 hasConcept C126322002 @default.
• W3097738629 hasConcept C132917006 @default.
• W3097738629 hasConcept C135763542 @default.
• W3097738629 hasConcept C141231307 @default.
• W3097738629 hasConcept C143998085 @default.
• W3097738629 hasConcept C153209595 @default.
• W3097738629 hasConcept C16671776 @default.
• W3097738629 hasConcept C21790070 @default.
• W3097738629 hasConcept C2776364478 @default.
• W3097738629 hasConcept C2779399171 @default.
• W3097738629 hasConcept C2781187634 @default.
• W3097738629 hasConcept C501734568 @default.
• W3097738629 hasConcept C502942594 @default.
• W3097738629 hasConcept C54355233 @default.
• W3097738629 hasConcept C71924100 @default.
• W3097738629 hasConcept C86803240 @default.
• W3097738629 hasConceptScore W3097738629C104317684 @default.
• W3097738629 hasConceptScore W3097738629C10590036 @default.
• W3097738629 hasConceptScore W3097738629C113968399 @default.
• W3097738629 hasConceptScore W3097738629C119054055 @default.
• W3097738629 hasConceptScore W3097738629C121608353 @default.
• W3097738629 hasConceptScore W3097738629C126322002 @default.
• W3097738629 hasConceptScore W3097738629C132917006 @default.
• W3097738629 hasConceptScore W3097738629C135763542 @default.
• W3097738629 hasConceptScore W3097738629C141231307 @default.
• W3097738629 hasConceptScore W3097738629C143998085 @default.
• W3097738629 hasConceptScore W3097738629C153209595 @default.
• W3097738629 hasConceptScore W3097738629C16671776 @default.
• W3097738629 hasConceptScore W3097738629C21790070 @default.
• W3097738629 hasConceptScore W3097738629C2776364478 @default.
• W3097738629 hasConceptScore W3097738629C2779399171 @default.
• W3097738629 hasConceptScore W3097738629C2781187634 @default.
• W3097738629 hasConceptScore W3097738629C501734568 @default.
• W3097738629 hasConceptScore W3097738629C502942594 @default.
• W3097738629 hasConceptScore W3097738629C54355233 @default.
• W3097738629 hasConceptScore W3097738629C71924100 @default.
• W3097738629 hasConceptScore W3097738629C86803240 @default.
• W3097738629 hasIssue "Supplement 1" @default.
• W3097738629 hasLocation W30977386291 @default.
• W3097738629 hasOpenAccess W3097738629 @default.
• W3097738629 hasPrimaryLocation W30977386291 @default.
• W3097738629 hasRelatedWork W1577303630 @default.
• W3097738629 hasRelatedWork W2258903631 @default.
• W3097738629 hasRelatedWork W2467412215 @default.
• W3097738629 hasRelatedWork W2526969807 @default.
• W3097738629 hasRelatedWork W2559098034 @default.
• W3097738629 hasRelatedWork W2605489051 @default.
• W3097738629 hasRelatedWork W2651057847 @default.
• W3097738629 hasRelatedWork W2757383627 @default.
• W3097738629 hasRelatedWork W3097738629 @default.
• W3097738629 hasRelatedWork W3193406861 @default.
• W3097738629 hasVolume "136" @default.
• W3097738629 isParatext "false" @default.
• W3097738629 isRetracted "false" @default.
• W3097738629 magId "3097738629" @default.
• W3097738629 workType "article" @default.